The report helps businesses gain a unique insight into the socio-economic dynamics, and helps analyze how they affect healthcare systems and their evolution. It can serve as a valuable tool with actionable guidance for sales, marketing, R&D and business managers with industry related interests.
Four chapters cover the numerical and written analysis for the following topics: Economic Outlook (38 Key industry indicators), The Healthcare System (HC system structures), Reforms (restructuring, re-engineering or austerity efforts) and the Healthcare Market (Capital Equipment, Medical Devices, Disposables and Pharmaceuticals).
The TforG report is accessible through a user friendly Business Intelligence tool. Licenses are valid for 1 year.
- Taiwan’s nominal GDP in 2015 was €430 bn, equivalent to €19,482 GDP per capita, with a growth rate of 3.7%. Taiwanese public debt is around 36% of GDP.
- The export lead economy has worldwide recognition and presence with its electronic equipment and components.
- In 2015 Taiwan performed well on international scales of competitiveness, ease of doing business, having a (low-risk) investment-friendly climate, and economic stability.
- The unemployment rate in Taiwan in 2015 is 4%.
The Healthcare System:
- The healthcare system is organized by the Ministry of Health and Welfare, under the Taiwanese government (ROC).
- Healthcare is considered highly accessibly, low cost, having short waiting times, providing a high extent of population and service coverage, and well organized in terms of data collection.
- Healthcare spending is 6.5% of GDP, equivalent to €1,187 per capita. 57% of the healthcare system costs in Taiwan are paid for via public funds, and 43% privately.
- Financing is provided by a centralized insurance scheme, the National Health Insurance Administration, in a single-payer model. The market is highly dominated by private providers and commercialization is becoming more popular.
- Some challenges facing the healthcare system include weak gatekeeping and pricing pharmaceuticals sustainably.
- Second Generation NHI (G2-NHI) (2013).
- Organization Act of the National Health Insurance Administration, Ministry of Health and Welfare (2013).
- Amendments made to the National Health Insurance Pharmaceutical Benefits and Reimbursement Schedule (2012-2013-2014)
- Guideline for Review and Approval of new chemical entities (2014)
- Healthcare expenditure per capita in Taiwan is rising; per capita expenditure is expected to rise as much as 26% in the next 3 years.
- The Taiwanese pharmaceutical market in 2015 was valued at €4.9 bn, with a forecasted growth of 4% in the next 3 years. The medical device market is valued at €2.1 bn, with a forecasted growth of 8% annually in the next 5 years.
- Some of Taiwan’s most prominent opportunities are its reliance and need to trade with importers of high-end tech medical devices; its skilled domestic capacity for OEM and ODM manufacturing; and Taiwan as stepping stone into China.
Includes tables centralizing all relevant data on socio-demographics, macroeconomics and national Healthcare.
National Care Provision data:
Provides an overview of the Healthcare demographics: Nation Care provision data, Intensive Care units, Operating rooms, Emergency Rooms, Hospital services, Healthcare professionals.
© TforG Group – All Rights Reserved.